当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
Prolastin; Prolastin-C, Alpha-1-Proteinase Inhibitor (Human)
申请企业
Grifols Therapeutics LLC
药品名称
Prolastin; Prolastin-C, Alpha-1-Proteinase Inhibitor (Human)
承诺描述
Conduct two clinical trials: Trial 1: A pilot study of the safety and pharmacokinetics of Prolastin-C administered weekly at a dose of 120 mg/kg. Trial 2: An adequately-powered study of clinically meaningful endpoints -Prolastin-C efficacy study using CT scans as the primary endpoint.
承诺状态描述
The study completion date has passed, and the study has not yet been completed.